戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 es for SSc-associated Raynaud phenomenon and digital ulcers.
2  and frequency of attacks, and resolution of digital ulcers.
3 ynaud's and skin ulcers, and of bosentan for digital ulcers.
4 ing the effect of treatment on prevention of digital ulcers.
5 ent, or mood, compared with patients without digital ulcers.
6   Bosentan can reduce the development of new digital ulcers.
7 , including acro-osteolysis, calcinosis, and digital ulcers.
8 eolysis (10 [37.0%] vs 62 [12.9%]; P < .01), digital ulcers (15 [55.6%] vs 173 [36.1%]; P = .04), and
9 ad a lower prevalence of previous or current digital ulcers (28.2% vs 53.1% in lcSSc; P < .001; and 6
10 ary assessments included healing of existing digital ulcers and evaluation of hand function using the
11  bosentan may be effective in preventing new digital ulcers and improving hand function in patients w
12 made in the classification and assessment of digital ulcers and in understanding ulcer pathogenesis,
13 scales and performed clinical assessments of digital ulcers and infarcts; patients completed the Heal
14                                    Recurrent digital ulcers are a manifestation of vascular disease i
15                                              Digital ulcers are a painful and disabling visible manif
16 ssification and assessment of SSc-associated digital ulcers are also covered, alongside an overview o
17                                              Digital ulcers are associated with a severe disease cour
18                                              Digital ulcers are of interest to a broad range of derma
19                                              Digital ulcers are often very painful and affect all asp
20                       Raynaud phenomenon and digital ulcers are treated with dihydropyridine calcium
21                               VAS scores for digital ulcers as rated by the patients were not consist
22  daily and stratified according to number of digital ulcers at baseline (</=3 or >3).
23                Fifty-nine patients (21%) had digital ulcers at baseline.
24  patients with systemic sclerosis and active digital ulcers at baseline.
25                             Patients who had digital ulcers at the time of entry in the study were at
26 imary outcome variable was the number of new digital ulcers developing during the 16-week study perio
27                                              Digital ulcers (DUs) occurring on the fingers in patient
28 rs and (for those with recurrent SSc-related digital ulcers) endothelin-1 receptor antagonism.
29  each trial was the cumulative number of new digital ulcers from baseline to week 16.
30                                  The VAS for digital ulcers, GI symptoms, and lung symptoms correlate
31                                Patients with digital ulcers had worse RCS, pain, HAQ disability (over
32 , bosentan, decreased the development of new digital ulcers in patients with SSc.
33                                              Digital ulcers in patients with systemic sclerosis are a
34 ty, pain, and psychological impact of RP and digital ulcers in SSc can be measured by a small set of
35 t the use of macitentan for the treatment of digital ulcers in this patient population.
36 mber of new systemic sclerosis (SSc)-related digital ulcers in two multinational clinical trials; and
37  and physician VAS ratings of RP activity, a digital ulcer/infarct measure, measures of disability an
38 inct domains: disease activity, RP measures, digital ulcer measures, and mood/tension.
39                          The presence of new digital ulcers or improvement in digital ulcers showed s
40 able effects on the occurrence of upper limb digital ulcers or on other vascular manifestations of lc
41   Quinapril did not affect the occurrence of digital ulcers or the frequency or severity of RP episod
42 treatment with macitentan did not reduce new digital ulcers over 16 weeks.
43              The adjusted mean number of new digital ulcers per patient over 16 weeks was 0.94 in the
44                                              Digital ulcers require a multidisciplinary approach with
45 ence of new digital ulcers or improvement in digital ulcers showed significant associations with the
46 reatments available to both prevent and heal digital ulcers, some of which are also used in Raynaud p
47 skin manifestations (onset of skin fibrosis, digital ulcers, telangiectasias, puffy fingers).
48  with systemic sclerosis and active ischemic digital ulcers, treatment with macitentan did not reduce
49   In DUAL-2, the adjusted mean number of new digital ulcers was 1.44 in the 3-mg macitentan group (n
50 rity of the Raynaud phenomenon and fewer new digital ulcers were seen in the epoprostenol group.
51 mited versus diffuse), or number of baseline digital ulcers were taken into account.